Clinical trials: Placebo, active
Fluid Overload
Controlled Fluid Removal in Critical Ill Patients With Fluid Overload in the Intensive Care Unit.
This study evaluates the benefits and harms of goal directed fluid removal with furosemide versus placebo in critical ill adult patients with fluid overload in the intensive care unit.
- Trial name
- GODIF (NCT04180397)
- Testing
- Furosemide, Isotonic saline
- Where
- 29 sites in Australia, Czechia and 7 more
- Volunteers
- 1,000 people
- Sponsor
- Morten H. Bestle
Acute Kidney Injury, Renal Insufficiency,Chronic
Finerenone for AKI: a Multicenter, Randomized, Placebo-Controlled Feasibility Pilot Trial
This study is testing whether finerenone, when compared to placebo, is a tolerable and safe intervention when administered in patients with acute kidney injury (AKI).
- Conditions
- Acute Kidney Injury, Renal Insufficiency,Chronic, Kidney Diseases
- Trial name
- FiPAKI (NCT07775482)
- Testing
- Finerenone (BAY94-8862 ) 10 mg
- Where
- Canada
- Volunteers
- 72 people
- Sponsor
- Jean-Maxime Côté
Depression - Major Depressive Disorder, Transcranial Magnetic Stimulation
Effects of Low-intensity Transcranial Magnetic Stimulation on Major Depressive Disorder, and on 5-hydroxyindoleacetic Acid and Brain-derived Neurotrophic Factor Levels
The goal of this randomised clinical trial is to evaluate the effects of transcranial magnetic stimulation (TMS) on major depressive disorder (MDD) and on the levels of 5-hydroxyindoleacetic acid (5-HIAA) and brain-derived…
- Conditions
- Depression - Major Depressive Disorder, Transcranial Magnetic Stimulation, Placebo
- Trial name
- NCT06667180
- Testing
- Low-intensity TMS
- Where
- Mexico
- Volunteers
- 40 people
- Sponsor
- Universidad de Guanajuato
FSGS
A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
DMX-200 (repagermanium) is a C-C chemokine receptor type 2 (CCR2) inhibitor that, when administered concurrently with an ARB, is designed to inhibit recruitment of monocytes implicated in the inflammatory chemokine environment of…
- Trial name
- ACTION3 (NCT05183646)
- Testing
- DMX-200
- Where
- 220 sites in United States, Argentina and 19 more
- Volunteers
- 286 people
- Sponsor
- Dimerix Bioscience Pty Ltd
Postoperative Analgesia After Unilateral Hip Arthroplasty
Efficacy and Safety of TRD205 Tablets for Postoperative Analgesia in Unilateral Total Hip Arthroplasty (Phase IIb)
This is a phase IIa, multicenter ,randomized, double-blind, Double-Dummy, Active- and placebo-controlled study designed to evaluate the efficacy, safety and kinetic characteristics of TRD205 tablets for postoperative analgesia…
- Trial name
- TRD205 (NCT07543796)
- Testing
- TRD205 Tablets, oral; 400 mg initial dose, then 200 mg q12h for 3 doses; total 4 doses, TRD205 Tablets, oral; 800 mg initial dose, then 400 mg q12h; total 4 doses, TRD205 Tablets, oral; 1200 mg initial dose, then 600 mg q12h; total 4 doses
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Beijing Tide Pharmaceutical Co., Ltd
Sleep Quality, Magnesium Deficiency
Efficacy of MAGNESIO TOTAL on Sleep Quality and Quality of Life in Adults
This randomized, double-blind, placebo-controlled trial evaluates whether MAGNESIO TOTAL, a dietary supplement containing magnesium bisglycinate and magnesium malate (215 mg elemental magnesium per day), improves sleep quality…
- Conditions
- Sleep Quality, Magnesium Deficiency, Sleep Initiation and Maintenance Disorders, Quality of Life
- Trial name
- NCT07894562
- Testing
- Magnesium bisglycinate and magnesium malate
- Where
- Spain
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- José Enrique de la Rubia Ortí, Ph
Non-small Cell Lung Cancer
A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer
To assess the efficacy and safety of Almonertinib versus placebo following chemoradiation in patients with stage III unresectable epidermal growth factor receptor mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC).
- Trial name
- NCT04951635
- Testing
- Almonertinib
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Prurigo Nodularis (PN)
A Study to Evaluate the Efficacy and Safety of AK139 in Patients With Prurigo Nodularis.
This is a multicenter, randomized, double-blind, placebo-controlled phase II clinical study to evaluate the efficacy and safety of AK139 in the treatment of subjects with prurigo nodularis.
- Trial name
- NCT07883213
- Testing
- AK139
- Volunteers
- 132 people
- Sponsor
- Akeso
Hematopoietic Stem Cell Transplantation, Thrombocytopenia
Comparison of Etamsylate Versus Placebo to Prevent Bleeding in HSCT
This study employs a prospective, randomized, double-blind, placebo-controlled design. It aims to compare the efficacy of etamsylate versus placebo in preventing bleeding complications in patients with thrombocytopenia following…
- Trial name
- NCT07442513
- Testing
- etamsylate
- Where
- China
- Volunteers
- 404 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Idiopathic Pulmonary Fibrosis
Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis
This is a Ph 2, randomized, double-blind, placebo-controlled global multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of PIPE-791 in participants with a diagnosis of Idiopathic Pulmonary…
- Trial name
- NCT07284459
- Testing
- PIPE-791 Dose A, PIPE-791 Dose B
- Where
- 108 sites in Argentina, Australia and 17 more
- Volunteers
- 324 people
- Sponsor
- Contineum Therapeutics
Cervical Intraepithelial Neoplasia Grade 1, Human Papillomavirus 16 Infection
Phase I/II Trial of Electroporation-Delivered pBI-4 Vaccine (TriGrid™ PVX4) for Treatment of Women With HPV16-Positive CIN1 or Persistent Infection
The purpose of this study is to evaluate the safety, efficacy, and tolerability of pBI-4, an investigational therapeutic DNA vaccine, in treating adult women with Human Papillomavirus type 16 (HPV16)-positive Grade 1 cervical…
- Trial name
- NCT07809997
- Testing
- pBI-4 Vaccine
- Where
- 2 sites in Taiwan
- Volunteers
- 94 people
- Sponsor
- Chang Gung Memorial Hospital
Healthy Volunteers
A Study of LY4178256 in Healthy Participants
The main purpose of this study is to evaluate how well LY4178256 is tolerated and what side effects may occur in healthy participants.
- Trial name
- NCT07698210
- Testing
- LY4178256
- Where
- 2 sites in United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Stress, Healthy Subjects
The Effects of Chicory Root-derived Prebiotic on Mood and Stress Responsiveness in Healthy Adults With Mild to Moderate Levels of Stress and Anxiety
Emerging evidence from preclinical research suggests that prebiotic fibres may play a beneficial role in supporting mental health through modulation of the gut-brain axis-a complex communication network linking the…
- Conditions
- Stress, Healthy Subjects, Anxiety, Mild to Moderate
- Trial name
- PRIME (NCT07058324)
- Testing
- Prebiotic fiber
- Where
- Germany
- Volunteers
- 204 people, healthy volunteers welcome
- Sponsor
- Beneo-Institute
Patients Undergoing Open Thyroid Surgery
Mecobalamin in Promoting Recurrent Laryngeal Nerve Function Recovery After Thyroid Surgery
Recurrent laryngeal nerve injury is one of the most common and serious complications affecting quality of life after thyroid surgery.
- Trial name
- MIREN (NCT07274696)
- Testing
- Mecobalamin
- Where
- China
- Volunteers
- 528 people
- Sponsor
- West China Hospital
Primary Prevention of Atherosclerotic Cardiovascular Disease
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c.) administered on Day 1, Day 90, and every 6 months thereafter in patients at…
- Trial name
- NCT05739383
- Testing
- Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
- Where
- 983 sites in United States, Argentina and 40 more
- Volunteers
- 14,012 people
- Sponsor
- Novartis Pharmaceuticals
Spasticity
A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.
The purpose of the study is to assess the safety and efficacy of increasing doses of Corabotase (also known as IPN10200) with the aim to evaluate the Pharmacodynamics (PD) profile of Corabotase and to establish the total…
- Trial name
- LANTIMA (NCT04752774)
- Testing
- Corabotase, Dysport
- Where
- 81 sites in United States, Austria and 12 more
- Volunteers
- 240 people
- Sponsor
- Ipsen
Healthy
A Study in Healthy Men to Test How Well Different Doses of BI 3776528 Are Tolerated
The trial aims to study the safety, tolerability, and pharmacokinetics of single and multiple rising doses of BI 3776528.
- Trial name
- NCT06745297
- Testing
- BI 3776528, short-acting benzodiazepine
- Where
- Germany
- Volunteers
- 172 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Osteoarthritis (OA) of the Knee
53-Week Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 With Mild to Severe Tibio-Femoral Osteoarthritis of the Knee
53-Week Study Evaluating the Safety and Efficacy of Intra-articular (IA) Injections of TPX-100 vs Placebo in Subjects with Mild to Severe Tibio-Femoral Osteoarthritis of the Knee
- Trial name
- NCT06865079
- Testing
- TPX-100 200mg, Once weekly for 4 weeks, PBS
- Where
- 33 sites in United States
- Volunteers
- 270 people
- Sponsor
- OrthoTrophix, Inc
Amyotrophic Lateral Sclerosis
Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS
The goal of this clinical trial is to learn if the drug pridopidine works to treat amyotrophic lateral sclerosis in adults. It will also help to learn about the safety of pridopidine.
- Trial name
- PREVAiLS (NCT07322003)
- Testing
- Pridopidine
- Where
- 56 sites in United States, Belgium and 11 more
- Volunteers
- 500 people
- Sponsor
- Prilenia
Chronic Urticaria, Idiopathic
A Phase 2 Study of MG-K10 in Chronic Spontaneous Urticaria
This Phase 2 study evaluates the efficacy and safety of MG-K10 in participants with chronic spontaneous urticaria inadequately controlled by second-generation H1-antihistamines.
- Trial name
- NCT07838727
- Testing
- MG-K10 Injection
- Volunteers
- 60 people
- Sponsor
- Shanghai Mabgeek Biotech.Co.Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.